Is Bal Pharma overvalued or undervalued?

Nov 15 2025 08:08 AM IST
share
Share Via
As of November 14, 2025, Bal Pharma's valuation has shifted to attractive, with a PE ratio of 18.76, an EV to EBITDA of 10.07, and a dividend yield of 1.49%, indicating it is fairly valued compared to peers like Sun Pharma and Divi's Lab, despite a year-to-date return of -34.27%.
As of 14 November 2025, Bal Pharma's valuation grade has moved from very attractive to attractive, indicating a shift in market perception. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 18.76, an EV to EBITDA of 10.07, and a dividend yield of 1.49%.

When compared to peers, Bal Pharma's PE ratio is significantly lower than Sun Pharma's 36.49 and Divi's Lab's 69.65, which are categorized as expensive, while it is on par with Cipla's attractive valuation of 22.72. Despite recent underperformance, with a year-to-date return of -34.27% compared to the Sensex's 8.22%, Bal Pharma's valuation suggests it is positioned reasonably within its sector.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News